Helen Knight
Tracked across 2 events · 14 articles · First seen Mar 31, 2026 · Last active Sep 17, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Regulatory
Impact: Helen Knight, director of medicines evaluation at United Kingdom — National Institute for Health and Care Research, commented on the compelling evidence from clinical trials supporting semaglutide's effectiveness.
Mar 31, 2026 · 7 articles
Regulatory
The United Kingdom — National Institute for Health and Care Research (NICE) reversed its July 2024 rejection of Enhertu (trastuzumab deruxtecan) and recommended the drug for routine NHS use in Bret Engemann for around 1,000…
Impact: NICE's director of medicines evaluation said the commercial solution and new assessment methods allowed the treatment to be provided on the NHS.
Sep 16, 2026 · 7 articles
ERGEN INTELLIGENCE
Track Helen Knight live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard